Contract Biomanufacturing Services Global Market – Forecast to 2025

Publishing Date : August, 2017
Report Code : HCBT0115
Price:
Single license $3,600
Site license $5,400
Global license $7,200


The contract biomanufacturing global market is expected to grow at double digit CAGR to reach $36.6 billion by 2025.

Biomanufacturing is a widely used term to describe manufacture of biologic molecules for various stages of drug development right from pre-clinical stage to commercial supply. The biologic drug manufacturing is a complex process involving huge capital and sound technical expertise. Many large and small pharmaceutical companies are turning to outsourcing the drug manufacture process to reduce capital investments on capacities and focus more on their core competencies. Contract manufacturing organizations, particularly for R&D and clinical trials, are making product manufacture, more efficient and often less costly. In addition to that, the use of single-use bioreactors is effectively reducing the manufacture facility cost. This option is more viable for smaller and low-funded companies for their in-house candidate product manufacturing needs, whereby, the companies can avoid $50-$150 million facility costs for construction of fixed, dedicated stainless steel bioreactor-based bioprocessing systems and outsource their manufacturing requirements to CMOs which use single-use facilities which typically cost $25-$40 million for commercial manufacture.

There is a continued growth of biopharmaceutical market which is expected to nearly double in next 10 years. This will be a result of continued new product approvals, expansion of indications for current products which include less-developed countries becoming more affluent and increased drug demand of the aging population in the U.S. and other major pharmaceutical markets. Aging populations are at a high risk of developing chronic diseases such as cancer and arthritis and these diseases are being precisely targeted using biopharmaceuticals. Many blockbuster drugs losing their exclusivity are also giving room for many biosimilar (and bio-betters) companies to enter into the world’s biopharmaceuticals market subsequently attracting many CROs, CDMOs, and CMOs to enter into the picture. Hence, there is every reason to assume that future growth in biopharmaceutical outsourcing will continue at a minimum X% in western countries to about X% in Asian countries.

Contract manufacturing market was estimated region wise with segmental revenues for various end user groups such as diagnostics, research reagents and therapeutics. Total available manufacturing capacity was estimated with distinction between GMP vs. non-GMP, in-house vs. CMOs and clinical vs. commercial contract manufacturing. Key developments such as collaborations, capacity expansions and acquisitions were reported and analyzed.

  • In depth assessment of all segments and sub segments of contract biomanufacturing global market
  • Regional analysis of contract biomanufacturing global market
  • Market dynamics for contract manufacturing
  • Market sizing based on end users
  • Emerging trends and strategies
  • Market share analysis of major players in contract manufacturing global market.
  • Competitive landscape with regard to capacities for major CMOs
  • CMO service matrix based on type of cell culture techniques, revenues and employee size 
  • 1     BIOLOGICS CONTRACT MANUFACTURING GLOBAL MARKET
    • 1.1     EXECUTIVE SUMMARY
  • 2     MARKET ANALYSIS
    • 2.1     FACTORS INFLUENCING MARKET
      • 2.1.1     DRIVERS AND OPPORTUNITIES
        • 2.1.1.1     GLOBALIZATION OF OUTSOURCING FOR BIOMANUFACTURING
        • 2.1.1.2     INCREASED FUNDING FROM PRIVATE INVESTORS AND GOVERNMENT FOR DEVELOPMENT OF CMOS
        • 2.1.1.3     EMERGENCE OF SINGLE USE BIOREACTORS
        • 2.1.1.4     INCREASING BIOLOGICS APPROVALS IN THE PAST YEAR
        • 2.1.1.5     SUCCESSFUL COLLABORATION AND LOW COST FOR OUTSOURCING
      • 2.1.2     RESTRAINTS AND THREATS
        • 2.1.2.1     HIGH REQUIREMENT FOR CAPITAL INVESTMENTS RESTRAINING MANY CMOS TO ENTER THE BIOLOGICS SPACE
        • 2.1.2.2     RISK OF PRODUCT CONTAMINATION & MAINTAINING HIGH PRODUCTIVITY
        • 2.1.2.3     ENTRY OF LARGE PHARMACEUTICAL COMPANY WITH EXESS CAPACITY INTO THE CMO MARKET
        • 2.1.2.4     STRINGENT REGULATIONS AND MANDATORY REQUIREMENT OF CGMP CERTIFICATIONS
  • 3     CONTRACT BIOMANUFACTURING SERVICES
    • 3.1.1     INTRODUCTION
  • 3.2     CONTRACT BIOMANUFACTURING, BY PROCESS
    • 3.2.1     BIOMANUFACTURING BY MAMMALIAN CELL CULTURE
    • 3.2.2     BIOMANUFACTURING BY MICROBIAL CELL CULTURE
    • 3.2.3     BIOMANUFACTURING BY OTHER CELL CULTURE
  • 3.3     CONTRACT BIOMANUFACTURING GLOBAL MARKET, BY END USERS
    • 3.3.1     CONTRACT BIOMANUFACTURING OF DIAGNOSTICS
    • 3.3.2     CONTRACT BIOMANUFACTURING OF RESEARCH REAGENTS
    • 3.3.3     CONTRACT BIOMANUFACTURING OF THERAPEUTICS
  • 3.4     CONTRACT BIOMANUFACTURING GLOBAL MARKET, BY REGION
  • 3.5     COMPETITIVE LANDSCAPE
    • 3.5.1     CAPACITY COMPARISON
    • 3.5.2     CONTRACT BIOMANUFACTURING GLOBAL MARKET SHARE, BY LEADING PLAYERS
  • 3.6     COMPANY DEVELOPMENTS
    • 3.6.1     MERGER AND ACQUISITION BY CMOS
    • 3.6.2     COLLABORATIONS
    • 3.6.3     CAPACITY EXPANSIONS
  • 4     COMPANY PROFILES
    • 4.1     ABZENA PLC
      • 4.1.1     OVERVIEW
      • 4.1.2     FINANCIALS
      • 4.1.3     SERVICE PORTFOLIO
      • 4.1.4     KEY DEVELOPMENTS
      • 4.1.5     SWOT ANALYSIS
    • 4.2     ALBANY MOLECULAR RESEARCH INC
      • 4.2.1     OVERVIEW
      • 4.2.2     FINANCIALS
      • 4.2.3     SERVICE PORTFOLIO
      • 4.2.4     KEY DEVELOPMENTS
      • 4.2.5     SWOT ANALYSIS
    • 4.3     ASAHI GLASS CO. LTD.
      • 4.3.1     OVERVIEW
      • 4.3.2     FINANCIALS
      • 4.3.3     SERVICE PORTFOLIO
      • 4.3.4     KEY DEVELOPMENTS
      • 4.3.5     SWOT ANALYSIS
    • 4.4     BOEHRINGER INGELHEIM
      • 4.4.1     OVERVIEW
      • 4.4.2     FINANCIALS
      • 4.4.3     SERVICE PORTFOLIO
      • 4.4.4     KEY DEVELOPMENTS
      • 4.4.5     SWOT ANALYSIS
    • 4.5     CATALENT INC.
      • 4.5.1     OVERVIEW
      • 4.5.2     FINANCIALS
      • 4.5.3     SERVICE PORTFOLIO
      • 4.5.4     KEY DEVELOPMENTS
      • 4.5.5     SWOT ANALYSIS
    • 4.6     CHARLES RIVER LABORATORIES
      • 4.6.1     OVERVIEW
      • 4.6.2     FINANCIALS
      • 4.6.3     SERVICE PORTFOLIO
      • 4.6.4     KEY DEVELOPMENTS
      • 4.6.5     SWOT ANALYSIS
    • 4.7     FUJIFILM HOLDINGS CORPORATION
      • 4.7.1     OVERVIEW
      • 4.7.2     FINANCIALS
      • 4.7.3     SERVICE PORTFOLIO
      • 4.7.4     KEY DEVELOPMENTS
      • 4.7.5     SWOT ANALYSIS
    • 4.8     HORIZON DISCOVERY GROUP, PLC
      • 4.8.1     OVERVIEW
      • 4.8.2     FINANCIALS
      • 4.8.3     SERVICE PORTFOLIO
      • 4.8.4     KEY DEVELOPMENTS
      • 4.8.5     SWOT ANALYSIS
    • 4.9     INNOVENT BIOLOGICS
      • 4.9.1     OVERVIEW
      • 4.9.2     FINANCIALS
      • 4.9.3     SERVICE PORTFOLIO
      • 4.9.4     KEY DEVELOPMENTS
      • 4.9.5     SWOT ANALYSIS
    • 4.1     JHL BIOTECH INC.
      • 4.10.1     OVERVIEW
      • 4.10.2     FINANCIALS
      • 4.10.3     SERVICE PORTFOLIO
      • 4.10.4     KEY DEVELOPMENTS
      • 4.10.5     SWOT ANALYSIS
    • 4.11     LONZA GROUP
      • 4.11.1     OVERVIEW
      • 4.11.2     FINANCIALS
      • 4.11.3     SERVICE PORTFOLIO
      • 4.11.4     KEY DEVELOPMENTS
      • 4.11.5     SWOT ANALYSIS
    • 4.12     MERCK KGAA
      • 4.12.1     OVERVIEW
      • 4.12.2     FINANCIALS
      • 4.12.3     PRODUCT PORTFOLIO
      • 4.12.4     KEY DEVELOPMENTS
      • 4.12.5     SWOT ANALYSIS
    • 4.13     PATHEON N.V.
      • 4.13.1     OVERVIEW
      • 4.13.2     FINANCIALS
      • 4.13.3     SERVICE PORTFOLIO
      • 4.13.4     KEY DEVELOPMENTS
      • 4.13.5     SWOT ANALYSIS
    • 4.14     PROTEOGENIX
      • 4.14.1     OVERVIEW
      • 4.14.2     FINANCIALS
      • 4.14.3     SERVICE PORTFOLIO
      • 4.14.4     KEY DEVELOPMENTS
      • 4.14.5     SWOT ANALYSIS
    • 4.15     RENTSCHLER BIOTECHNOLOGIE GMBH
      • 4.15.1     OVERVIEW
      • 4.15.2     FINANCIALS
      • 4.15.3     SERVICE PORTFOLIO
      • 4.15.4     KEY DEVELOPMENTS
      • 4.15.5     SWOT ANALYSIS
    • 4.16     SELEXIS SA
      • 4.16.1     OVERVIEW
      • 4.16.2     FINANCIALS
      • 4.16.3     SERVICE PORTFOLIO
      • 4.16.4     KEY DEVELOPMENTS
      • 4.16.5     SWOT ANALYSIS
    • 4.17     SYNGENE INTERNATIONAL
      • 4.17.1     OVERVIEW
      • 4.17.2     FINANCIALS
      • 4.17.3     SERVICE PORTFOLIO
      • 4.17.4     KEY DEVELOPMENTS
      • 4.17.5     SWOT ANALYSIS
    • 4.18     WUXI APPTEC
      • 4.18.1     OVERVIEW
      • 4.18.2     FINANCIALS
      • 4.18.3     SERVICE PORTFOLIO
      • 4.18.4     KEY DEVELOPMENTS
      • 4.18.5     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     CAPACITY COMPARISON OF CONTRACT MANUFACTURING ORGANIZATIONS V’S IN-HOUSE CAPACITIES (L)
      • TABLE 2     CONTRACT BIOMANUFACTURING GLOBAL MARKET REVENUE, BY STAGE ($BN)
      • TABLE 3     CONTRACT MANUACTURING ORGANIZATIONS CAPACITY, BY PROCESS (L)
      • TABLE 4     CONTRACT BIOMANUFACTURING GLOBAL MARKET REVENUE, BY PROCESS ($BN)
      • TABLE 5     ANTICANCER DRUGS SYNTHESIZED IN MICROBIAL CELL CULTURE
      • TABLE 6     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET BY END USERS ($BN)
      • TABLE 7     SECOND GENERATION PROTEIN THERAPEUTICS
      • TABLE 8     THERAPEUTIC VACCINES IN PIPELINE
      • TABLE 9     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET BY REGION ($BN)
      • TABLE 10     COMPANY COMPARISON MATRIX, BY MANUFACTURING CAPABILITY
      • TABLE 11     MERGERS AND ACQUITIONS (2015-2017)
      • TABLE 12     COLLABORATIONS (2016-2017)
      • TABLE 13     CAPACITY EXPANSIONS (2016-2017)
      • TABLE 14     ABZENA PLC: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 15     ABZENA PLC: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 16     ALBANY MOLECULAR RESEARCH INC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 17     ALBANY MOLECULAR RESEARCH INC: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 18     ALBANY MOLECULAR RESEARCH: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 19     ASAHI GLASS CO. LTD.: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 20     ASAHI GLASS CO. LTD. : TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 21     BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 22     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 23     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 24     CATALENT INC: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 25     CATALENT INC: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 26     CATALENT INC: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 27     CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 28     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 29     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 30     FUJIFILM HOLDINGS CORPORATION : TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 31     FUJIFILM HOLDINGS CORPORATION : TOTAL REVENUE, BY SEGMENTS (2014-2016) ($MN)
      • TABLE 32     FUJIFILM HOLDINGS CORPORATION : TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 33     HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 34     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 35     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 36     LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 37     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 38     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 39     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 40     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 41     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 42     PATHEON N.V.: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 43     PATHEON N.V.: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 44     SYNGENE INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 45     SYNGENE INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 46     WUXI APPTEC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)

      LIST OF FIGURES

      • FIGURE 1     MARKET DYNAMICS
      • FIGURE 2     INDUSTRY PIPELINE FOR SMALL MOLECULE V’S BIOLOGICS
      • FIGURE 3     GLOBAL MANUFACTURING CAPACITY, CGMP V’S NON-CGMP, INHOUSE V’S CMO, 2016
      • FIGURE 4     CAPACITY UTILIZATION OF CONTRACT MANUFACTURING ORGANIZATIONS, BY STAGE (L)
      • FIGURE 5     CONTRACT BIOMANUFACTURING GLOBAL MARKET REVENUE, BY STAGE ($BN)
      • FIGURE 6     CAPACITY COMPARISON OF MAMMALIAN, MICROBIAL AND OTHER CULTURE SYSTEMS (L)
      • FIGURE 7     CONTRACT BIOMANUFACTURING GLOBAL MARKET REVENUE, BY PROCESS ($BN)
      • FIGURE 8     BIO-MANUFACTURING OUTSOURCING GLOBAL MARKET, BY END USERS ($BN)
      • FIGURE 9     OUTLOOK OF BIOLOGICS CMO GLOBAL MARKET, BY REGION ($BN) AND PRODUCTION IN METRIC TONS, 2016
      • FIGURE 10     CAPACITY COMPOSITION OF TOP 10 CONTRACT MANUFACTURING ORGANIZATIONS (L)
      • FIGURE 11     MARKET SHARE ANALYSIS BY CONTRACT MANUFACTURING MAJOR PLAYERS, 2016
      • FIGURE 12     COMPANY DEVELOPMENTS (2016-2017)
      • FIGURE 13     OVERVIEW: ABZENA PLC
      • FIGURE 14     SWOT: ABZENA PLC
      • FIGURE 15     OVERVIEW: ALBANY MOLECULAR RESEARCH INSTITUTE
      • FIGURE 16     SWOT: ALBANY MOLECULAR RESEARCH, INC
      • FIGURE 17     OVERVIEW: ASAHI GLASS CO. LTD.
      • FIGURE 18     SWOT: ASAHI GLASS CO. LTD.
      • FIGURE 19     OVERVIEW: BOEHRINGER INGELHEIM
      • FIGURE 20     SWOT: BOEHRINGER INGELHEIM
      • FIGURE 21     OVERVIEW: CATALENT INC.
      • FIGURE 22     SWOT: CATALENT INC.
      • FIGURE 23     OVERVIEW: CHARLES RIVER LABORATORIES
      • FIGURE 24     SWOT: CHARLES RIVER LABORATORIES
      • FIGURE 25     OVERVIEW: FUJIFILM HOLDINGS CORPORATION
      • FIGURE 26     SWOT: FUJIFILM DIOSYNTH BIOTECHNOLOGIES
      • FIGURE 27     OVERVIEW: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 28     SWOT: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 29     SWOT: INNOVENT BIOLOGICS
      • FIGURE 30     SWOT: JHL BIOTECH INC.
      • FIGURE 31     OVERVIEW: LONZA GROUP
      • FIGURE 32     SWOT: LONZA GROUP
      • FIGURE 33     OVERVIEW: MERCK KGAA
      • FIGURE 34     SWOT: MERCK KGAA
      • FIGURE 35     OVERVIEW: PATHEON N.V.
      • FIGURE 36     SWOT: PATHEON N.V.
      • FIGURE 37     SWOT: PROTEOGENIX
      • FIGURE 38     SWOT: RENTSCHLER BIOTECHNOLOGIE
      • FIGURE 39     SWOT: SELEXIS SA
      • FIGURE 40     OVERVIEW: SYNGENE INTERNATIONAL
      • FIGURE 41     SWOT: SYNGENE INTERNATIONAL
      • FIGURE 42     SWOT: WUXI APPTEC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABBVIE
      • 2     ABNOVA
      • 3     ABZENA
      • 4     AFFINITY LIFESCIENCES
      • 5     AGC ASAHI GLASS (CMC BIOLOGICS)
      • 6     ALEXION PHARMACEUTICALS
      • 7     AMRI
      • 8     ANOGEN
      • 9     AVID BIOSERVICES
      • 10     BHARAT BIOTECH LTD
      • 11     BINEX CO. LTD.
      • 12     BIOCONNECT LIFE SCIENCES
      • 13     BIODEXTRIS
      • 14     BIOGEN
      • 15     BIORELIANCE SAFC
      • 16     BOEHRINGER INGELHEIM
      • 17     CADILA HEALTHCARE LTD
      • 18     CATALENT INC.
      • 19     CELLTRION
      • 20     CHARLES RIVER LABORATORIES
      • 21     COBRA BIOLOGICS
      • 22     COOK PHARMICA
      • 23     COVANCE RESEARCH PRODUCTS
      • 24     CROWN BIOSCIENCES
      • 25     CYTOVANCE BIOLOGICS
      • 26     DENDREON CORPORATION
      • 27     DIATHEVA
      • 28     ENVIGO
      • 29     EUROFINS
      • 30     EUROPA BIOPRODUCTS
      • 31     EVOTEC
      • 32     FAPON
      • 33     FUJIFILM DIOSYNTH BIOTECHNOLOGIES
      • 34     GTP TECHNOLOGY
      • 35     HORIZON DISCOVERY
      • 36     IMMUNOREAGENTS
      • 37     INNO BIOLOGICS
      • 38     INNOVENT BIO
      • 39     INTAS PHARMACEUTICALS
      • 40     JHL BIOTECH
      • 41     JSR CORPORATION (KBI BIOPHARMA)
      • 42     JUBILANT HOLLISTERSTIER
      • 43     KEMWELL BIOPHARMA
      • 44     LAKE PHARMA
      • 45     LAMPIRE BIOLOGICAL LABORATORIES
      • 46     LFB BIOMANUFACTUING
      • 47     LONZA
      • 48     LUINA BIO
      • 49     MENARINI BIOTECH S.R.L
      • 50     MERCK GMBH
      • 51     MILTENYI BIOTECH GMBH
      • 52     NOVASEP
      • 53     OMNIA BIOLOGICS
      • 54     PARAGON BIOSERVICES
      • 55     PATHEON
      • 56     PREMAS BIOTECH PVT LTD
      • 57     PROTEOGENIX
      • 58     RENTSCHLER BIOTECHNOLOGIE
      • 59     SAMSUNG BIOLOGICS
      • 60     SANDOZ GMBH
      • 61     SCRIPPS LABORATORIES
      • 62     SELEXIS S.A.
      • 63     SERUM INSTITUTE OF INDIA
      • 64     SYNGENE
      • 65     THERAPURE BIOPHARMA
      • 66     TOYOBO CO. LTD.
      • 67     U-PROTEIN EXPRESS BV
      • 68     VIFOR PHARMA LTD
      • 69     WAISMAN CLINICAL BIOMANUFACTURING
      • 70     WUXI APPTEC
      • 71     XCELLEREX
      • 72     ZYMEWORKS INC.